View Exam | PowerPak

1. Which of the following is the threshold recommended by the 2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway (ECDP) for when to consider a nonstatin medication in addition to maximally tolerated statin therapy in a patient with ASCVD and multiple comorbidities?

A. LDL-C of 70 mg/dL B. LDL-C of 100 mg/dL C. 30% reduction in LDL-C from baseline D. Non–high-density lipoprotein cholesterol (non–HDL-C) of 130 mg/dL

2. Which of the following is the threshold recommended by the 2017 ECDP for when to consider a nonstatin medication in addition to maximally tolerated statin therapy in a 35-year-old patient without clinical ASCVD and a baseline LDL-C of 230 mg/dL?

A. LDL-C of 70 mg/dL B. Non–HDL-C of 100 mg/dL C. 50% reduction in LDL-C from baseline D. 30%-49% reduction in LDL-C from baseline

3. Which potential side effect was evaluated in the EBBINGHAUS study and was shown to be no different from evolocumab therapy with extended use?

A. Cataracts B. Neurocognitive side effects C. Creatine kinase values > 5 times upper limit of normal D. Aminotransferase values > 3 times upper limit of normal

4. What are the long-term effects of adding evolocumab therapy for patients with stable ASCVD who are already treated with maximally tolerated statin therapy?

A. Decreased CV events and an increased risk of cataracts B. No change in CV events, but a greater than 50% decrease in LDL-C C. Decreased CV events and an increased risk of injection site reactions D. No change in CV events, but a trend toward decreased risk of major CV events after 2.2 years

5. A patient with ASCVD, recurrent ASCVD events, and multiple high-risk factors is on rosuvastatin 40 mg daily and ezetimibe 10 mg daily. Alirocumab 300 mg every 4 weeks is started because the patient is above the ACC-recommended threshold; 4 weeks later, the patient reports development of a rash. Which of the following is the most appropriate recommendation for this patient?

A. Stop alirocumab therapy B. Continue therapy and use an antihistamine daily C. Decrease the dose of alirocumab to 75 mg every 2 weeks D. Continue therapy and provide ongoing monitoring to see if the rash worsens

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is the threshold recommended by the 2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway (ECDP) for when to consider a nonstatin medication in addition to maximally tolerated statin therapy in a patient with ASCVD and multiple comorbidities?

2. Which of the following is the threshold recommended by the 2017 ECDP for when to consider a nonstatin medication in addition to maximally tolerated statin therapy in a 35-year-old patient without clinical ASCVD and a baseline LDL-C of 230 mg/dL?

3. Which potential side effect was evaluated in the EBBINGHAUS study and was shown to be no different from evolocumab therapy with extended use?

4. What are the long-term effects of adding evolocumab therapy for patients with stable ASCVD who are already treated with maximally tolerated statin therapy?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is the threshold recommended by the 2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway (ECDP) for when to consider a nonstatin medication in addition to maximally tolerated statin therapy in a patient with ASCVD and multiple comorbidities?

2. Which of the following is the threshold recommended by the 2017 ECDP for when to consider a nonstatin medication in addition to maximally tolerated statin therapy in a 35-year-old patient without clinical ASCVD and a baseline LDL-C of 230 mg/dL?

3. Which potential side effect was evaluated in the EBBINGHAUS study and was shown to be no different from evolocumab therapy with extended use?

4. What are the long-term effects of adding evolocumab therapy for patients with stable ASCVD who are already treated with maximally tolerated statin therapy?

« Return to Activity

Customers who Purchased
this Activity also Purchased